Clinical trial
A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"
NCT00334464 · Intermountain Health Care, Inc., Other · Completed
Key facts
| NCT number | NCT00334464 |
|---|---|
| Title | A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study" |
| Official title | A Controlled Clinical Pharmacogenetic Study of a CYP2C9 Plus VKORC1 Polymorphism-Based Individualized Dosing Algorithm for Warfarin to Increase Efficiency of Achieving Therapeutic Dosing |
| Lead sponsor | Intermountain Health Care, Inc., Other |
| Collaborators | Deseret Foundation LDS Hospital Cardiovascular Research |
| Status | Completed |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism |
| Intervention type | Drug |
| Interventions | Standard of care or genotyping dosing of warfarin dosing |
| Enrollment | 200 |
| Start date | Feb 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Jun 7, 2006 |
| Last update posted | Aug 21, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: